Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression
Trial Parameters
Brief Summary
Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic, and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.
Eligibility Criteria
Inclusion Criteria: 1. Hospitalization with community acquired pneumonia (CAP) confirmed by pulmonary infiltrate in chest imaging 2. Valid informed consent form 3. Working diagnosis of CAP by enrolling physician 4. No hospitalization for any reason within 28 days prior to hospitalization for the current episode of CAP 5. At least 2 out of the five following clinical symptoms: * Fever * Cough * Purulent sputum * Shortness of breath or need for respiratory support * Crackling or rales on auscultation, dullness to percussion, or bronchial breathing 6. At least 1 of the following criteria * Known HIV infection or AIDS * Anti-tumor treatment within the past six months * Therapy with corticosteroids ≥ 20mg for ≥ 14 days before enrollment * Non-steroidal immunosuppressive therapy within the past six months * Cytostatic therapy within the past six months * Radiation therapy within the past six months * Bone marrow transplant received * Respiratory support at home via tracheostoma * Cystic fibr